Action NetraMark - PF0

NetraMark Holdings Inc (PF0) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,39

( - )

Prix Achat

0,389

Prix Vente

0,413

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

0,353 Plage de 52 semaines 1,11

Clôture Veille

0,39

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

5 016

Volume financier

VWAP

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

This agreement represents NetraMark's ninth commercial contract since the start of its current fiscal year and...

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Announces Change To Board Of Directors

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.001	0.25706940874	0.389	0.421	0.353	4928	0.39711298	DE
4	-0.12	-23.5294117647	0.51	0.51	0.353	2920	0.43517497	DE
12	-0.106	-21.3709677419	0.496	0.664	0.353	5016	0.52070854	DE
26	-0.32	-45.0704225352	0.71	0.77	0.353	9020	0.59691895	DE
52	-0.445	-53.2934131737	0.835	1.11	0.353	11860	0.76891907	DE
156	-0.485	-55.4285714286	0.875	1.23	0.353	16458	0.85580159	DE
260	-0.485	-55.4285714286	0.875	1.23	0.353	16458	0.85580159	DE

PF0 - Frequently Asked Questions (FAQ)

What is the current NetraMark Holdings Inc share price?

The current share price of NetraMark Holdings Inc is 0,39 €

What is the 1 year trading range for NetraMark Holdings Inc share price?

NetraMark Holdings Inc has traded in the range of 0,353 € to 1,11 € during the past year

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NetraMark Holdings Inc (PF0)

NetraMark Holdings Inc (PF0) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

PF0 Dernières nouvelles

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

PF0 - Frequently Asked Questions (FAQ)

PF0 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NetraMark Holdings Inc (PF0)

NetraMark Holdings Inc (PF0) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

PF0 Dernières nouvelles

NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company

NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

PF0 - Frequently Asked Questions (FAQ)

PF0 Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités